Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Vizimpro On Course For India But Competitive Arena Awaits

Executive Summary

Pfizer’s Vizimpro has been endorsed by an expert panel in India, paving the way for its potential introduction on the market, where other EGFR inhibitors including AstraZeneca’s Tagrisso have a head start.

Advertisement

Related Content

Basilea-Pfizer’s Cresemba Heads For Indian Debut
AZ, Pfizer, Lilly Novel Anticancers Head For India Debut
New EU Approvals
Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
Will 'Financial Toxicity’ Weigh Down 1L NSCLC Win For Tagrisso In India?
BI Aims To ‘Own’ Indian Lung Cancer Space As Afatinib Debuts

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125361

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel